Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
The Infectious Diseases Society of America now recommends annual high-dose or adjuvanted influenza vaccine and a single RSV dose for most immunocompromised persons; timing around immunosuppression and household immunization are emphasized.
A phase 3 trial of Pfizer’s quadrivalent modified mRNA influenza vaccine (n≈18,476) showed 34.5% relative efficacy vs a licensed inactivated vaccine for laboratory-confirmed influenza (A strains) with higher reactogenicity but low rates of
A multicenter phase 2 randomized trial found no differential benefit of adaptive computerized cognitive training, structured cognitive rehabilitation, or transcranial direct current stimulation (tDCS) versus active comparators for self‑repo
Emerging H3N2 subclade K has driven increased influenza activity abroad and may seed the 2025–26 northern hemisphere season. Surveillance gaps complicate risk assessment; vaccination and early antiviral use remain central clinical strategie
An adult male in Washington has tested positive for avian flu, marking a resurgence after 9 months. This article explores the scientific evidence, recent outbreaks, and practical advice to prevent infection.
A Phase III trial of ganaplacide‑lumefantrine (GanLum, KLU156) met its primary non‑inferiority endpoint vs artemether‑lumefantrine, with a PCR‑corrected Day‑29 cure rate of 97.4% (estimand). The drug combines a novel mechanism (ganaplacide)
A 37-year-old man developed meningoencephalitis caused by a novel mammarenavirus genetically related to Lassa virus after travel to Chad, highlighting emergence of a new pathogen with distinct clinical features.
Phase 2 studies demonstrate that elebsiran, a small interfering RNA, combined with PEG-IFNα, enhances sustained HBsAg loss rates in chronic HBV infection, offering a promising approach toward functional cure.
The CARES phase 3b trial in Africa found cabotegravir + rilpivirine long‑acting injections every 8 weeks noninferior to continued oral ART for viral suppression at 96 weeks, with an acceptable safety profile and implementation consideration
In PASO‑DOBLE, switching virologically suppressed adults to dolutegravir/lamivudine maintained viral suppression at 48 weeks and was non‑inferior to switching to bictegravir/emtricitabine/tenofovir alafenamide, supporting shared decision‑ma
In STRIDE‑7, the adult‑specific 21‑valent conjugate vaccine V116 produced robust opsonophagocytic responses across all 21 serotypes and had a favorable tolerability profile in adults living with HIV, supporting broader serotype coverage com
The GAME CHANGER randomized trial found cefiderocol non‑inferior to standard‑of‑care antibiotics for 14‑day mortality in hospital‑acquired and healthcare‑associated Gram‑negative bloodstream infection; no superiority was seen, including in
The CloCeBa trial found cefazolin non‑inferior to cloxacillin for meticillin‑susceptible Staphylococcus aureus (MSSA) bacteraemia, with similar 90‑day composite outcomes and substantially lower rates of serious adverse events and acute kidn
A prespecified pooled analysis of two large randomised pragmatic trials (DANFLU-2 and GALFLU) found high‑dose influenza vaccine reduced hospitalisation for influenza or pneumonia by 8.8% versus standard‑dose in adults ≥65 years, with larger
Post hoc analysis of the MELODY Phase 3 trial shows nirsevimab reduced RSV-associated lower respiratory tract infections and RSV coinfections in healthy term and late-preterm infants, with no signal of viral replacement by other respiratory
A nationwide retrospective study from Chile finds that a universal nirsevimab immunisation strategy in 2024 reduced RSV-related lower respiratory tract infection hospitalisations by 76% and ICU admissions by 85%, with an NNT of 35 to preven
A multicentre retrospective TriNetX analysis found reduced odds of RSV test-positivity for infants receiving nirsevimab when last dose was within 6–11 months before testing; protection was strongest within 6 months and not evident beyond 12
Real-world surveillance from 2024–2025 shows substantial reductions in RSV-associated hospitalizations among infants after broad availability of maternal RSV vaccination and nirsevimab, with effectiveness estimates approximating those from
A phase 1 trial of the rVSV‑vectored Lassa vaccine demonstrated dose-dependent transient reactogenicity, no vaccine‑related serious adverse events or hearing loss, and robust, durable humoral and cellular responses across doses and lineages
A large Asian cohort study shows serum HBsAg <100 IU/mL reliably identifies inactive chronic hepatitis B patients whose annual HCC risk is <0.2%, potentially allowing de‑escalation of surveillance and informing partial HBV cure defini
Open language-specific specialty feeds and department pages.